In the current frantic M&A climate, it's like waving a red flag at a bull. Shire's first quarter results have beat expectations, and the hyperactivity and rare disease specialist has raised its forecast for annual earnings growth.
In the current frantic M&A climate, it's like waving a red flag at a bull. Shire's first quarter results have beat expectations, and the hyperactivity and rare disease specialist has raised its forecast for annual earnings growth.
"Our sharpened strategy, the addition of Cinryze from the ViroPharma acquisition (scripintelligence.com, 11 November 2013) and our continued focus...
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
